Michael von Bergwelt-Baildon
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Immunotherapy | 9 | 2019 | 2421 | 1.39 | Why? |
| CD40 Antigens | 4 | 2017 | 118 | 1.36 | Why? |
| Antigen-Presenting Cells | 3 | 2017 | 206 | 0.98 | Why? |
| Hematopoiesis | 1 | 2021 | 168 | 0.86 | Why? |
| Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 121 | 0.75 | Why? |
| Hematology | 3 | 2021 | 649 | 0.69 | Why? |
| Tumor Microenvironment | 2 | 2017 | 264 | 0.62 | Why? |
| Antigens, Neoplasm | 1 | 2017 | 230 | 0.60 | Why? |
| Neoplasms | 12 | 2021 | 17251 | 0.60 | Why? |
| Internal Medicine | 1 | 2021 | 557 | 0.58 | Why? |
| Hemostasis | 1 | 2021 | 811 | 0.56 | Why? |
| Hematologic Diseases | 1 | 2020 | 614 | 0.51 | Why? |
| Immune System Diseases | 1 | 2017 | 410 | 0.50 | Why? |
| Dinoprostone | 1 | 2012 | 101 | 0.47 | Why? |
| B-Lymphocytes | 4 | 2017 | 4418 | 0.44 | Why? |
| Programmed Cell Death 1 Receptor | 4 | 2019 | 724 | 0.42 | Why? |
| Cell Communication | 1 | 2013 | 396 | 0.42 | Why? |
| Dendritic Cells | 2 | 2017 | 1330 | 0.36 | Why? |
| Antineoplastic Agents | 6 | 2020 | 3550 | 0.35 | Why? |
| T-Lymphocytes | 5 | 2019 | 6670 | 0.32 | Why? |
| Colorectal Neoplasms | 1 | 2019 | 1884 | 0.29 | Why? |
| Graft vs Host Disease | 1 | 2008 | 501 | 0.27 | Why? |
| Immunotherapy, Adoptive | 2 | 2019 | 524 | 0.27 | Why? |
| Skin Neoplasms | 1 | 2017 | 1679 | 0.25 | Why? |
| Lymphocytes, Tumor-Infiltrating | 3 | 2018 | 130 | 0.25 | Why? |
| Coculture Techniques | 2 | 2013 | 258 | 0.24 | Why? |
| Receptors, Antigen, T-Cell | 2 | 2018 | 760 | 0.23 | Why? |
| Antibodies, Monoclonal | 2 | 2019 | 8041 | 0.22 | Why? |
| CTLA-4 Antigen | 2 | 2019 | 282 | 0.21 | Why? |
| Psychiatric Rehabilitation | 1 | 2020 | 65 | 0.20 | Why? |
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2018 | 10 | 0.19 | Why? |
| Embolism | 1 | 2020 | 136 | 0.19 | Why? |
| Protein Kinases | 1 | 2019 | 93 | 0.19 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 1510 | 0.18 | Why? |
| Growth Inhibitors | 1 | 2017 | 7 | 0.18 | Why? |
| Radioimmunotherapy | 1 | 2017 | 5 | 0.17 | Why? |
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 179 | 0.17 | Why? |
| B7-H1 Antigen | 2 | 2018 | 541 | 0.17 | Why? |
| Combined Modality Therapy | 4 | 2019 | 3395 | 0.17 | Why? |
| Cell Cycle Checkpoints | 1 | 2017 | 126 | 0.16 | Why? |
| Natural Killer T-Cells | 1 | 2018 | 191 | 0.16 | Why? |
| Small Cell Lung Carcinoma | 1 | 2018 | 133 | 0.16 | Why? |
| Lassa Fever | 1 | 2017 | 88 | 0.16 | Why? |
| Lymphoma, B-Cell | 1 | 2017 | 166 | 0.15 | Why? |
| Transplantation, Homologous | 1 | 2019 | 757 | 0.15 | Why? |
| Interleukin-4 | 1 | 2017 | 367 | 0.15 | Why? |
| Radiosurgery | 1 | 2018 | 249 | 0.15 | Why? |
| Lymphocyte Activation | 2 | 2017 | 2742 | 0.15 | Why? |
| Cell Proliferation | 2 | 2013 | 1973 | 0.14 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.14 | Why? |
| Medical Oncology | 3 | 2021 | 3826 | 0.14 | Why? |
| Evidence-Based Practice | 1 | 2020 | 693 | 0.14 | Why? |
| Candidemia | 1 | 2019 | 353 | 0.14 | Why? |
| Hodgkin Disease | 1 | 2017 | 204 | 0.13 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2018 | 604 | 0.13 | Why? |
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2012 | 3 | 0.13 | Why? |
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2012 | 5 | 0.13 | Why? |
| Vasculitis | 1 | 2020 | 691 | 0.13 | Why? |
| Receptors, CCR7 | 1 | 2012 | 40 | 0.13 | Why? |
| Cell Shape | 1 | 2012 | 57 | 0.13 | Why? |
| Chemotaxis | 1 | 2012 | 67 | 0.13 | Why? |
| Neoplasm Proteins | 1 | 2018 | 501 | 0.13 | Why? |
| NIH 3T3 Cells | 1 | 2012 | 147 | 0.13 | Why? |
| CD40 Ligand | 1 | 2013 | 121 | 0.13 | Why? |
| Humans | 38 | 2021 | 930598 | 0.12 | Why? |
| Antigens, CD | 1 | 2018 | 984 | 0.12 | Why? |
| Receptors, CXCR4 | 1 | 2012 | 83 | 0.12 | Why? |
| Phenotype | 4 | 2020 | 4037 | 0.12 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.12 | Why? |
| Antibodies | 1 | 2019 | 846 | 0.12 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1014 | 0.12 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.11 | Why? |
| Brain Neoplasms | 1 | 2018 | 669 | 0.11 | Why? |
| Polymorphism, Genetic | 1 | 2018 | 1074 | 0.11 | Why? |
| Molecular Targeted Therapy | 2 | 2017 | 1579 | 0.11 | Why? |
| Blood Coagulation Disorders | 2 | 2021 | 2040 | 0.10 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.10 | Why? |
| Kidney Diseases | 1 | 2020 | 1434 | 0.10 | Why? |
| Carcinoma, Squamous Cell | 1 | 2017 | 902 | 0.09 | Why? |
| Critical Care | 3 | 2021 | 14081 | 0.09 | Why? |
| Immunomodulation | 1 | 2017 | 1472 | 0.09 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.09 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.09 | Why? |
| Mice | 3 | 2018 | 21357 | 0.08 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.08 | Why? |
| Melanoma | 1 | 2018 | 1229 | 0.08 | Why? |
| Blood Cell Count | 1 | 2013 | 1101 | 0.08 | Why? |
| Neutrophils | 2 | 2020 | 5476 | 0.08 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.08 | Why? |
| Palliative Care | 2 | 2019 | 2665 | 0.08 | Why? |
| Lung Diseases | 1 | 2020 | 2361 | 0.08 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 5277 | 0.08 | Why? |
| Renin-Angiotensin System | 1 | 2021 | 3661 | 0.07 | Why? |
| Information Dissemination | 1 | 2021 | 2986 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.07 | Why? |
| Head and Neck Neoplasms | 1 | 2017 | 1568 | 0.07 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.07 | Why? |
| Respiratory Insufficiency | 3 | 2020 | 7301 | 0.07 | Why? |
| Immunity, Cellular | 1 | 2017 | 3614 | 0.07 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
| Delivery of Health Care | 2 | 2020 | 15909 | 0.07 | Why? |
| Germany | 4 | 2021 | 9196 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.06 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.06 | Why? |
| Animals | 6 | 2019 | 78931 | 0.06 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Biomarkers | 3 | 2020 | 23361 | 0.06 | Why? |
| Cells, Cultured | 1 | 2013 | 5835 | 0.06 | Why? |
| Practice Guidelines as Topic | 3 | 2021 | 15421 | 0.06 | Why? |
| Thrombosis | 2 | 2020 | 7504 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2018 | 5837 | 0.05 | Why? |
| Lung Neoplasms | 1 | 2018 | 3228 | 0.05 | Why? |
| Neoplasm Staging | 2 | 2017 | 1999 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.05 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.05 | Why? |
| Cell Line, Tumor | 2 | 2018 | 3608 | 0.05 | Why? |
| Social Media | 1 | 2021 | 5798 | 0.05 | Why? |
| Oncology Nursing | 1 | 2021 | 156 | 0.05 | Why? |
| Apyrase | 1 | 2018 | 39 | 0.05 | Why? |
| Mutation | 1 | 2019 | 12376 | 0.05 | Why? |
| Travel | 1 | 2017 | 7220 | 0.05 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.04 | Why? |
| Togo | 1 | 2017 | 95 | 0.04 | Why? |
| Infectious Disease Medicine | 1 | 2021 | 311 | 0.04 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Contact Tracing | 1 | 2017 | 8448 | 0.04 | Why? |
| Risk Adjustment | 1 | 2021 | 730 | 0.04 | Why? |
| Platelet Activation | 1 | 2020 | 660 | 0.04 | Why? |
| Neoplasm Grading | 1 | 2017 | 400 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 9335 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Withholding Treatment | 1 | 2021 | 798 | 0.04 | Why? |
| Lung | 2 | 2020 | 31049 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.04 | Why? |
| Organ Dysfunction Scores | 1 | 2021 | 1475 | 0.03 | Why? |
| Male | 10 | 2021 | 367725 | 0.03 | Why? |
| Psychosocial Support Systems | 1 | 2020 | 710 | 0.03 | Why? |
| Candida | 1 | 2019 | 425 | 0.03 | Why? |
| Societies, Medical | 2 | 2021 | 6907 | 0.03 | Why? |
| Oncologists | 1 | 2021 | 877 | 0.03 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.03 | Why? |
| Drug Synergism | 1 | 2017 | 833 | 0.03 | Why? |
| Treatment Outcome | 2 | 2017 | 51732 | 0.03 | Why? |
| Female | 9 | 2021 | 380317 | 0.03 | Why? |
| Advance Care Planning | 1 | 2019 | 426 | 0.03 | Why? |
| Immunophenotyping | 1 | 2017 | 1290 | 0.03 | Why? |
| Extracellular Traps | 1 | 2020 | 1036 | 0.03 | Why? |
| Robotic Surgical Procedures | 1 | 2018 | 787 | 0.03 | Why? |
| Standard of Care | 1 | 2017 | 1297 | 0.03 | Why? |
| Disease Models, Animal | 2 | 2018 | 10998 | 0.03 | Why? |
| Risk Management | 1 | 2017 | 1044 | 0.02 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.02 | Why? |
| Blood Platelets | 1 | 2020 | 1704 | 0.02 | Why? |
| Disease Outbreaks | 1 | 2017 | 27595 | 0.02 | Why? |
| Middle Aged | 7 | 2021 | 270681 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Infection Control | 1 | 2017 | 23131 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2021 | 3228 | 0.02 | Why? |
| Hematologic Neoplasms | 1 | 2021 | 2105 | 0.02 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2018 | 3347 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.02 | Why? |
| Aged | 5 | 2020 | 215776 | 0.02 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2017 | 4758 | 0.02 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.02 | Why? |
| Adult | 5 | 2020 | 244371 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Fear | 1 | 2019 | 3607 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Communication | 1 | 2019 | 5206 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.01 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.01 | Why? |
| Patient Admission | 1 | 2017 | 5250 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2017 | 5762 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.01 | Why? |
| Critical Illness | 1 | 2017 | 17281 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Quarantine | 1 | 2017 | 18418 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |